SCHEMBL905181

SCHEMBL905181

CS(=O)(=O)Nc1ccc(Cl)cc1F

nearest known ligand 0.58

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 4/20 0.54
TAS2R14 Q9NYV8 1/20 0.47
TSHR P16473 1/20 0.47
TRPV1 Q8NER1 1/20 0.46
KIF11 P52732 1/20 0.46
NR3C1 P04150 1/20 0.45
PGR P06401 1/20 0.45
NR3C2 P08235 1/20 0.45
AR P10275 1/20 0.45
KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3792756 0.82 KIF11 (0.50) CCR2TSHRKIF11
SCHEMBL19303541 0.82 PSIP1 (0.59) CCR2TAS2R14TSHRPGRKMT2A
SCHEMBL10626704 0.81 PTGS2 (0.56) TSHRKMT2A
SCHEMBL14906059 0.81 MCL1 (0.61) CCR2TSHRKIF11
SCHEMBL19997315 0.81 CCR2 (0.50) CCR2TAS2R14TSHRKMT2A
SCHEMBL8091420 0.80 CA2 (0.51)
SCHEMBL27183177 0.80 CA1 (0.47) CCR2TAS2R14TSHRKMT2A
SCHEMBL13855804 0.79
SCHEMBL2760253 0.79 MAPT (0.48) CCR2KIF11
SCHEMBL11560825 0.79 MCL1 (0.59) CCR2TSHRKIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020146657-A1 PI4-KINASE INHIBITORS WITH ANTI-CANCER ACTIVITY THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2020-07-16 WO disclosed
WO-2017147526-A1 PI-KINASE INHIBITORS WITH ANTI-INFECTIVE ACTIVITY THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2017-08-31 WO disclosed
US-20160194314-A1 PI-KINASE INHIBITORS WITH ANTI-INFECTIVE ACTIVITY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-07-07 US disclosed
EP-2621915-B1 NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES DAE WOONG PHARMA (KR) 2016-04-20 EP disclosed
US-9309236-B2 PI-kinase inhibitors with broad spectrum anti-infective activity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2016-04-12 US disclosed
US-9040572-B2 Method of preparing benzoimidazole derivatives DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-05-26 US disclosed
US-20150051193-A1 PI-kinase Inhibitors with Broad Spectrum Anti-Infective Activity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2015-02-19 US disclosed
US-20130231477-A1 NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2013-09-05 US disclosed
EP-2621915-A2 NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES Daewoong Pharmaceutical Co., Ltd (KR) 2013-08-07 EP disclosed
WO-2012044043-A2 NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051193-A1 PI-kinase Inhibitors with Broad Spectrum Anti-Infective Activity PIP4K2A, PIP5K1A, PIP4K2C CCR2 4238/4885TAS2R14 1075/4885TSHR 4541/4885
US-20130231477-A1 NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES BRD1, BRD4, VAT1 CCR2 3389/4885TAS2R14 773/4885TSHR 3570/4885
US-20160194314-A1 PI-KINASE INHIBITORS WITH ANTI-INFECTIVE ACTIVITY PIP4K2A, PIP5K1A, PIP4K2C CCR2 3995/4885TAS2R14 1442/4885TSHR 4361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.